A corporate venture capital investor headquartered in Asia is an investment arm of a large drug development organization. The firm invests globally across all stages, from Seed through later-stage financings. In addition to providing capital, the firm offers strategic and operational support spanning drug development, regulatory planning, partnering, and commercialization. The firm leverages the broader capabilities and infrastructure of its affiliated organization to help portfolio companies accelerate growth and value creation.  
 
The firm focuses on pharmaceuticals, biotechnology, and medical devices, with a strong emphasis on drug discovery and translational innovation. The firm seeks differentiated therapeutic and medical technology opportunities with strong scientific foundations and commercial potential. Within therapeutics, the firm is modality-agnostic and evaluates opportunities across a broad range of disease areas and development stages, from discovery through clinical development. The firm also participates in licensing, incubation, and strategic business development activities designed to advance promising healthcare technologies.  
 
From a company and management team perspective, the firm seeks founders and leadership teams with strong scientific expertise, differentiated intellectual property, and credible development strategies. The firm prioritizes opportunities supported by high-quality translational science and works closely with management teams to provide development resources, business development support, partnering opportunities, and commercialization expertise. Through its strategic network and operational capabilities, the firm helps portfolio companies accelerate development timelines and expand global market access. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A capital and private equity investor with a flexible investment mandate invests across a wide range of stages and sectors. On the venture capital side, the firm typically participates in Seed through Series B financings and is open to both leading and co-investing. Investments are generally made through special purpose vehicles, with typical allocation sizes ranging from approximately $2M to $20M. The firm primarily focuses on opportunities within the United States.  

Within healthcare and life sciences, the firm invests in therapeutics, medical devices, digital health, and diagnostics. For therapeutics, the firm prefers opportunities that are approaching clinical development or already in clinical trials. Within medical devices, the firm focuses on technologies that are nearing regulatory approval or have already obtained clearance or approval. The firm is disease-agnostic and evaluates opportunities based on the strength of the technology, clinical potential, and commercial opportunity.  

From a company and management team perspective, the firm generally prefers board representation and seeks to work closely with portfolio companies to support strategic growth and value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the United States focuses on Pre-Seed through Series A opportunities across deeptech, life sciences, and the convergence of technology and healthcare. Backed by family offices and strategic investors across multiple regions, the firm benefits from a network of partners with entrepreneurial and life sciences expertise. The firm typically participates as a co-investor with check sizes ranging from approximately $100K to $1M. In addition to venture investing, the firm collaborates with capital partners on strategic acquisition opportunities and actively supports company formation and incubation. The firm invests globally and assists portfolio companies with expansion into emerging markets across Asia, Africa, and other regions. 

The firm takes an opportunistic approach to life sciences and deeptech investing. Key areas of interest include artificial intelligence, health technology, neuroscience, life science tools, and therapeutics. The firm is also open to orphan disease opportunities. Within therapeutics, the firm focuses on companies from the preclinical stage through Phase I clinical development. The firm seeks differentiated technologies with the potential to create meaningful scientific, clinical, or commercial impact. 

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition and does not require board representation as a condition of investment. The firm prefers to support founders through collaborative partnerships and strategic guidance while maintaining flexibility in investment structure and governance. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a corporate venture capital arm of a leading healthcare and diagnostics company based in Asia. The firm focuses on investing in later-stage life sciences and healthcare companies, typically from growth-stage financings through post-IPO opportunities. The firm generally makes investments below $10M per company and maintains a selective investment strategy. The firm evaluates opportunities globally and leverages the expertise, industry relationships, and commercial infrastructure of its parent organization to support portfolio companies.  

The firm primarily focuses on therapeutics and diagnostics, while remaining open to select medical device and digital health opportunities. Within therapeutics, the firm is most interested in programs ranging from mid- to late-stage clinical development through commercial-stage assets. Areas of interest include cardiovascular diseases, respiratory diseases, oncology, autoimmune disorders, urology, and central nervous system disorders. Within in vitro diagnostics, the firm is open to a broad range of technologies spanning development-stage through clinical and commercial applications.  

From a company and management team perspective, the firm seeks technologies with strong scientific foundations, clear commercial potential, and a high likelihood of successfully navigating regulatory approval pathways. As a strategic investor, the firm prioritizes opportunities that demonstrate meaningful differentiation and long-term market potential. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global healthcare-focused impact venture capital fund affiliated with a broader healthcare innovation platform is headquartered in Asia. The firm invests equity capital into technology-enabled healthcare companies, typically deploying investments ranging from approximately $500K to $2M. The firm targets opportunities from Pre-Series A through Series B stages and seeks companies capable of delivering both measurable healthcare impact and strong financial returns. The firm invests globally, with particular interest in solutions that can scale across domestic markets as well as other emerging healthcare markets.  

The firm focuses on technologies that improve healthcare access, outcomes, and quality of care. Core investment themes include preventive healthcare and self-care solutions, healthy aging and longevity, holistic wellness, and AI-enabled hospital technologies. The firm prioritizes scalable digital health platforms, data-driven healthcare technologies, and tech-enabled services addressing systemic healthcare challenges across provider systems, hospital infrastructure, and consumer health channels.  

From a company and management team perspective, the firm seeks teams with strong operational execution, clearly defined impact objectives, and the ability to scale across diverse healthcare environments. The firm prioritizes companies with validated technologies, credible commercial models, and realistic market adoption strategies. Beyond capital, the firm provides portfolio companies with access to strategic partnerships, healthcare providers, hospital systems, and regional expansion support across Southeast Asia and other high-growth markets. The firm is open to acting as either a lead investor or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture investment arm of an international healthcare and pharmaceutical organization is focused on advancing innovative patient-centered solutions. The firm invests in early-stage life sciences companies developing breakthrough therapeutics, medical devices, digital health technologies, nutraceuticals, and medical foods. The firm prioritizes opportunities aligned with key strategic healthcare areas and supports portfolio companies through industry expertise and international commercial networks.  

The firm focuses on respiratory diseases, central nervous system and neurological disorders, and women’s health. Within women’s health, areas of particular interest include urinary tract infections, vaginal infections, and related unmet healthcare needs. The firm evaluates opportunities across therapeutics, diagnostics, digital health, medical devices, nutraceuticals, and medical foods that can improve patient access, disease management, and quality of care. The firm does not invest in oncology and generally avoids technologies designed exclusively for inpatient or hospital-only environments, preferring solutions accessible in broader patient-care settings.  

In addition to early-stage investments, the firm is open to strategic collaborations with companies that already have commercialized products and are seeking international expansion opportunities. The firm leverages the broader organization’s global infrastructure and commercial presence to support geographic growth and market access.  

From a company and management team perspective, the firm seeks teams with strong scientific or clinical expertise and a clear commitment to impactful innovation. While prior industry experience is viewed positively, the firm remains open to working with promising founders and syndicate partners aligned with its strategic focus areas. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A life sciences-focused venture capital firm with offices in Europe focuses on disruptive early-stage life sciences companies and invests primarily in therapeutics. The firm is actively investing through its latest fund and has built a portfolio of multiple startups through both direct investments and company creation initiatives. The firm invests predominantly in Europe, with a strong emphasis on opportunities in Western Europe. 
 
The firm invests primarily in therapeutics and does not currently focus on medical devices, diagnostics, or digital health. The firm is modality-agnostic and evaluates a broad range of therapeutic approaches. Areas of strongest interest include oncology, immuno-oncology, rare and orphan diseases, infectious diseases, and immunology. The firm typically invests from preclinical through early clinical stages and focuses on opportunities with the potential to become first- or best-in-class therapies. 
 
From a company and management team perspective, the firm is open to working with both experienced operators and first-time entrepreneurs and has supported several companies led by first-time CEOs. The firm places strong emphasis on diversity in leadership and maintains a hands-on investment approach, actively mentoring and supporting portfolio companies. The firm is open to acting as either a lead investor or co-investor and works closely with scientific founders, academic institutions, and syndicate partners to help companies scale and mature. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.